Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

breakoutstock Jun. 8 at 5:15 PM

$NKTR all that has changed are traders chasing IPO and hot stocks. They will come back and run this up. There is so much AI trading that it distorts reality. Like a bumble bee 🐝 sad.

0 · Reply

maxr96 Jun. 8 at 3:09 PM

$NKTR action reminds of that kid at school that kept being picked at just for being different

3 · Reply

PraxisTrade Jun. 8 at 9:53 AM

$NKTR $VWAV $ARTV $DGXX <<..

0 · Reply

george4it Jun. 5 at 5:33 PM

$NKTR Adding again. Too cheap to ignore. People are going to lose so much chasing the SpaceX IPO.

0 · Reply

breakoutstock Jun. 5 at 3:57 PM

No side effects. $NKTR just remember that.

0 · Reply

calbucs Jun. 5 at 12:23 PM

$NKTR This needs to get back its Mojo , let’s get back to $3 to 5 increases daily , look at APGE , over $90 and climbing . That should be us . Need some news from company soon .

0 · Reply

george4it Jun. 4 at 7:36 PM

$LLY This will be $NKTR pride in a year of LLY doesn’t buy them before then.

0 · Reply

WiseGuyInvestin Jun. 4 at 5:45 PM

$NKTR Lesson: when a stock doesn’t have one single green trading day in a month and a half, that’s CLEARLY manipulation. If you got weak hands, then you’re the sucker that the manipulators are taking advantage of.

4 · Reply

BK217 Jun. 4 at 5:31 PM

$NKTR my fellow shareholders, how does it feel to back one of the worst management teams in all of history

1 · Reply

calbucs Jun. 4 at 2:21 PM

$NKTR Are we finally over the hump here . Could we have back to back up days . About time !!

1 · Reply

Nektar Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:15 PM EDT - 5 days ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2026, 1:20 PM EDT - 5 days ago

Nektar Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 6:15 PM EDT - 12 days ago

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

2026-05-11T17:15:19.000Z - 4 weeks ago

Nektar price target lowered to $80 from $95 at Wedbush

2026-05-08T11:17:20.000Z - 4 weeks ago

Nektar price target raised to $192 from $105 at Piper Sandler

May 7, 2026, 5:00 PM EDT - 4 weeks ago

Nektar Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 4 weeks ago

Nektar Therapeutics Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 4 weeks ago

Nektar Therapeutics Quarterly report: Q1 2026

2026-05-07T20:52:57.000Z - 4 weeks ago

Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)

May 7, 2026, 4:15 PM EDT - 4 weeks ago

Nektar Therapeutics Reports First Quarter 2026 Financial Results

Apr 28, 2026, 6:00 PM EDT - 5 weeks ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

Apr 24, 2026, 8:00 AM EDT - 6 weeks ago

Nektar Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 6 weeks ago

Nektar Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 4:15 PM EDT - 6 weeks ago

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 21, 2026, 9:30 PM EDT - 6 weeks ago

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

2026-04-21T15:55:35.000Z - 6 weeks ago

Nektar price target raised to $95 from $70 at Wedbush

2026-04-21T10:56:02.000Z - 6 weeks ago

Nektar price target raised to $151 from $123 at Citi

2026-04-20T20:06:22.000Z - 7 weeks ago

Nektar announces $250M common stock offering

Apr 20, 2026, 4:01 PM EDT - 7 weeks ago

Nektar Therapeutics Announces Proposed Public Offering

2026-04-20T16:07:46.000Z - 7 weeks ago

Nektar rises 28.2%

Apr 20, 2026, 11:43 AM EDT - 7 weeks ago

This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.

2026-04-20T15:12:00.000Z - 7 weeks ago

Nektar rises 19.4%

2026-04-20T15:02:50.000Z - 7 weeks ago

Nektar price target raised to $185 from $165 at H.C. Wainwright

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Nektar Therapeutics Transcript: Study update

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Nektar Therapeutics Press release: Study update

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Nektar Therapeutics Slides: Study update

2026-04-20T11:49:42.000Z - 7 weeks ago

Nektar reports new results from Phase 2b REZOLVE-AA study

Apr 20, 2026, 7:30 AM EDT - 7 weeks ago

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

Apr 19, 2026, 12:00 PM EDT - 7 weeks ago

Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

Apr 9, 2026, 8:23 AM EDT - 2 months ago

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

2026-04-07T14:25:39.000Z - 2 months ago

Citi opens ‘upside 30-day catalyst watch’ on Nektar into data

Mar 31, 2026, 2:50 PM EDT - 2 months ago

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

2026-03-29T15:40:07.000Z - 2 months ago

Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

Mar 28, 2026, 12:36 PM EDT - 2 months ago

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

2026-03-24T11:15:28.000Z - 2 months ago

Nektar initiated with a Neutral at Wedbush

Mar 20, 2026, 10:00 AM EDT - 2 months ago

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

Mar 12, 2026, 5:00 PM EDT - 3 months ago

Nektar Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 3 months ago

Nektar Therapeutics Annual report: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 3 months ago

Nektar Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:15 PM EDT - 3 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 5:58 PM EDT - 3 months ago

NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Mar 9, 2026, 7:10 AM EDT - 3 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)

Mar 4, 2026, 9:10 AM EST - 3 months ago

Nektar Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:00 PM EST - 3 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

Feb 24, 2026, 6:00 PM EST - 3 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in March

Feb 17, 2026, 7:00 AM EST - 3 months ago

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

Feb 13, 2026, 4:15 PM EST - 4 months ago

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 13, 2026, 9:30 AM EST - 4 months ago

Can NKTR Stock Sustain Its 1,000% Rally?

Feb 11, 2026, 10:23 PM EST - 4 months ago

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

Feb 10, 2026, 8:00 AM EST - 4 months ago

Nektar Therapeutics Transcript: Study result

Feb 10, 2026, 8:00 AM EST - 4 months ago

Nektar Therapeutics Press release: Study result

Feb 10, 2026, 8:00 AM EST - 4 months ago

Nektar Therapeutics Slides: Study result

Feb 10, 2026, 7:00 AM EST - 4 months ago

New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

Feb 9, 2026, 4:15 PM EST - 4 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Jan 15, 2026, 6:58 PM EST - 5 months ago

Nektar.io Introduces DIRT: Materials Management for the Construction Industry

Dec 16, 2025, 8:00 AM EST - 6 months ago

Nektar Therapeutics Transcript: Study Result

Dec 16, 2025, 8:00 AM EST - 6 months ago

Nektar Therapeutics Press release: Study Result

Dec 16, 2025, 8:00 AM EST - 6 months ago

Nektar Therapeutics Slides: Study Result

Dec 15, 2025, 6:00 PM EST - 6 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Nov 20, 2025, 6:00 AM EST - 7 months ago

Nektar Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 8, 2025, 5:45 PM EST - 7 months ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 6, 2025, 5:00 PM EST - 7 months ago

Nektar Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Nektar Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Nektar Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:15 PM EST - 7 months ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 7 months ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 7 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 7 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 8:45 AM EDT - 9 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 15, 2025, 2:30 PM EDT - 9 months ago

Nektar Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:30 AM EDT - 9 months ago

Nektar Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:00 AM EDT - 9 months ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 3, 2025, 7:00 PM EDT - 9 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Nektar Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Nektar Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Nektar Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:15 PM EDT - 10 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 11 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 11 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 1 year ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 24, 2025, 1:20 PM EDT - 1 year ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 8:15 AM EDT - 1 year ago

Nektar Therapeutics Transcript: Study Update

Jun 24, 2025, 8:15 AM EDT - 1 year ago

Nektar Therapeutics Press release: Study Update

Jun 24, 2025, 8:15 AM EDT - 1 year ago

Nektar Therapeutics Slides: Study Update

Jun 24, 2025, 7:35 AM EDT - 1 year ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

breakoutstock Jun. 8 at 5:15 PM

$NKTR all that has changed are traders chasing IPO and hot stocks. They will come back and run this up. There is so much AI trading that it distorts reality. Like a bumble bee 🐝 sad.

0 · Reply

maxr96 Jun. 8 at 3:09 PM

$NKTR action reminds of that kid at school that kept being picked at just for being different

3 · Reply

PraxisTrade Jun. 8 at 9:53 AM

$NKTR $VWAV $ARTV $DGXX <<..

0 · Reply

george4it Jun. 5 at 5:33 PM

$NKTR Adding again. Too cheap to ignore. People are going to lose so much chasing the SpaceX IPO.

0 · Reply

breakoutstock Jun. 5 at 3:57 PM

No side effects. $NKTR just remember that.

0 · Reply

calbucs Jun. 5 at 12:23 PM

$NKTR This needs to get back its Mojo , let’s get back to $3 to 5 increases daily , look at APGE , over $90 and climbing . That should be us . Need some news from company soon .

0 · Reply

george4it Jun. 4 at 7:36 PM

$LLY This will be $NKTR pride in a year of LLY doesn’t buy them before then.

0 · Reply

WiseGuyInvestin Jun. 4 at 5:45 PM

4 · Reply

BK217 Jun. 4 at 5:31 PM

$NKTR my fellow shareholders, how does it feel to back one of the worst management teams in all of history

1 · Reply

calbucs Jun. 4 at 2:21 PM

$NKTR Are we finally over the hump here . Could we have back to back up days . About time !!

1 · Reply

Marolaca Jun. 4 at 2:02 PM

$ABVX $NKTR This will be a beautiful *almost lock step as one acheives success the other will follow.

0 · Reply

PercyFinn Jun. 4 at 1:51 PM

$NKTR https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3471132:0-nktr-global-phase-iii-trials-for-a-novel-treg-agonist-target-broad-immune-diseases-with-first-data-in-2028/

0 · Reply

BK217 Jun. 4 at 1:39 PM

$NKTR $ABVX soaring back and we remain stuck. Go figure lol

1 · Reply

calbucs Jun. 4 at 12:32 PM

$NKTR Pathetic paid per post loser !! Blocked

1 · Reply

OMNIFALL Jun. 3 at 5:56 PM

$NKTR shitty, boring conference event. jefferies guy texted during the entire thing and kept winking at the camera. nektar guy got nervous as fuck about how they are charging blindly into ph3 and have frauded their data

4 · Reply

Marolaca Jun. 3 at 3:47 PM

$NKTR

1 · Reply

Baldchinese Jun. 3 at 3:02 PM

$NKTR i am legit so confused as to why this stock is so weak. Great data, maybe a bit too much dillution but still. Straight down for more than a month now. Mc below 2B

1 · Reply

george4it Jun. 3 at 12:16 PM

$NKTR You just never know….

0 · Reply

JuggernautRaider Jun. 3 at 12:15 PM

A friend of mine asked me about $TTRX … my advice, I’d stay away. It is a stock you can trade if you know what you’re doing, but I don’t trade options $TNXP $NKTR $NUVB are all better options in JUST MY opinion. I did this analysis In a few minutes making coffee before work. I saved this friend thousands of dollars in pain and angst - TTRX looks like a dog, not a Juggernaut, to the Bonesaw of biotech I enjoy assessing companies for fun educational purposes. Not always right but i’m also not always wrong - usually i hit on 3 out of 4 🧮

0 · Reply

Marolaca11 Jun. 2 at 10:45 PM

$NKTR I am sure many funds will find this price irresistible

1 · Reply

yourock Jun. 2 at 8:24 PM

$NKTR what happened here?

1 · Reply

lilBobbyBagholder Jun. 2 at 7:02 PM

$NKTR Hard to believe this was $100 not long ago

0 · Reply

Market Cap	1.94B
Revenue (ttm)	55.23M
Net Income (ttm)	-164.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-297.08%
Debt to Equity Ratio	0.00

Volume	1,000,100
Avg Vol	1,062,134
Day's Range	N/A - N/A
Shares Out	33.79M
Stochastic %K	11%
Beta	1.13
Analysts	Strong Sell
Price Target	$153.25